1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Leqembi Safety Is Focus Of Three Postmarketing Requirements From US FDA

 
• By Sue Sutter

Required studies will assess the risks of ARIA and intracerebral hemorrhage, as well as safety in ApoE ε4 homozygotes. For the required registry-based study, the FDA suggests use of the ALZ-NET platform with no mention of CMS’ newly established registry, which may lack the level of detailed information needed to satisfy the drug regulator’s request.

Arrows on road
When Leqembi converted to full approval, Eisai traded a required confirmatory trial for three mandatory safety studies. • Source: Shutterstock

With the US Food and Drug Administration’s full approval of the Alzheimer’s drug Leqembi (lecanemab-irmb), Eisai Co., Ltd. traded a confirmatory trial requirement under accelerated approval for three mandatory postmarketing safety studies.

Key Takeaways

  • The FDA is requiring Eisai to conduct three postmarketing safety studies of Leqembi focused on concerns highlighted in labeling about ARIA, intracerebral hemorrhage and risks in...

Exercising its drug safety authority under Section 505(o) of the Food, Drug and Cosmetic Act, the FDA is requiring Eisai to conduct three studies to assess the serious risks of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role

 
• By Sue Sutter

By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.